CelLBxHealth PLC - Q2 and First Half Year Results ended 30 June 2026

CelLBxHealth plc
("CelLBxHealth" or "the Company")
Q2 and First Half Year Results ended
Q2 revenue increased 100% over Q1 and annualised burn rate reduced by 61%
CelLBxHealth Executive Chairman,
"We have created a leaner, more commercially focused business, strengthened our strategic partnerships and the strong growth in Q2 revenue is an early sign of the successful implementation of our revised commercial strategy. Our unique live CTC platform addresses an important unmet clinical need, and we remain focused on disciplined execution as we convert this growing opportunity into sustainable revenue growth."
Financial Highlights
|
● |
Q2 revenue of |
|
● |
H1 revenue of |
|
● |
Gross profit of |
|
● |
Operating loss significantly reduced to |
|
● |
Loss after tax of |
|
● |
Restructuring programme substantially delivered, reducing the annualised operating cash cost base to approximately |
|
● |
Cash and cash equivalents of |
Operational Highlights
|
● |
Commercial momentum strengthened during the period, with revenue increasing significantly from Q1 to Q2 |
|
● |
Master Services Agreement now in place with AstraZeneca |
|
● |
Collaboration with AdventHealth for two clinical studies evaluating CTCs to improve cancer care |
|
● |
Research collaboration signed with The Royal Marsden NHS Foundation Trust evaluating CTC-DNA profiling in advanced non-small cell lung cancer where ctDNA testing is uninformative |
|
● |
Strategic collaborations progressed with QIAGEN, Roche Diagnostics, Illumina and Myriad |
|
● |
Sub-lease on US facility effective |
Post closing events
|
● |
On |
Outlook
|
● |
FY2026 revenues remain expected to be at least |
|
● |
Significantly reduced operating cost base and improved cash utilisation provide cash runway into Q2 2027 |
|
● |
The Board believes the strategic actions implemented during late 2025 into 2026 established a leaner, more focused and commercially aligned platform for future growth |
|
● |
Commercial weighted pipeline of |
|
● |
On the back of further revenue growth, the Board expects to be EBITDA positive in 2028 |
For further information:
|
CelLBxHealth plc |
via Walbrook PR |
|
|
|
|
Cavendish (NOMAD and Broker) |
+44 (0)20 7220 0500 |
|
|
|
|
Walbrook PR (Investor and Media Relations) |
Tel: +44 (0)20 7933 8780 or CelLBx@walbrookpr.com Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
Notes for editors
About CelLBxHealth plc
CelLBxHealth plc is a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.
Commercial focus spans three revenue streams - Product Sales of the Parsortix platform and consumables through CRO and clinical lab partnerships, Laboratory Services including clinical trial support and assay development delivered from a GCLP-compliant
For more information, visit https://cellbxhealth.com/.
CELLBXHEALTH PLC
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE SIX MONTHS ENDED
|
|
|
Period ended (Unaudited) |
|
Period ended (Unaudited) |
|
Year ended (Audited) |
|||||
|
|
Note |
£'000 |
|
£'000 |
|
£'000 |
|||||
|
Revenue |
|
597 |
|
796 |
|
1,351 |
|||||
|
Cost of sales |
|
(233) |
|
(330) |
|
(519) |
|||||
|
Gross profit |
|
364 |
|
466 |
|
832 |
|||||
|
Other operating income |
2 |
169 |
|
- |
|
956 |
|||||
|
Operating costs |
|
(3,184) |
|
(10,143) |
|
(21,037) |
|||||
|
Operating loss |
|
(2,651) |
|
(9,677) |
|
(19,249) |
|||||
|
Finance income |
|
50 |
|
96 |
|
126 |
|||||
|
Finance costs |
|
(68) |
|
(151) |
|
(285) |
|||||
|
Loss before tax |
|
(2,669) |
|
(9,732) |
|
(19,408) |
|||||
|
Tax (charge)/credit |
2 |
(32) |
|
464 |
|
(101) |
|||||
|
Loss for the period |
|
(2,701) |
|
(9,268) |
|
(19,509) |
|||||
|
|
|
|
|
|
|
|
|||||
|
Other comprehensive income/(loss) Items that may be subsequently reclassified to profit or loss |
|
|
|
|
|
|
|||||
|
Exchange differences on translating foreign operations |
|
(370) |
|
2,107 |
|
1,625 |
|||||
|
Other comprehensive income/(loss) |
|
(370) |
|
2,107 |
|
1,625 |
|||||
|
Total comprehensive loss for the period |
|
(3,071) |
|
(7,161) |
|
(17,884) |
|||||
|
|
|
|
|
|
|
|
|||||
|
Loss per share attributable to owners of the parent |
|
|
|
|
|
|
|||||
|
Basic and Diluted (pence per share) |
3 |
(0.24) |
|
(2.87) |
|
(5.51) |
|||||
|
All activity arose from continuing operations.
|
|
|
|
|
|
|
|||||
CELLBXHEALTH PLC
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT
|
|
|
|
30 June 2026 (Unaudited) |
|
30 June 2025 (Unaudited) |
|
(Audited) |
|
|
|
|
Note |
|
£'000 |
|
£'000 |
|
£'000 |
|
Assets |
|
|
|
|
|
|
|
|
|
Non-current assets |
|
|
|
|
|
|
|
|
|
Intangible assets |
|
|
|
270 |
|
2,631 |
|
390 |
|
Property, plant and equipment |
|
|
|
801 |
|
2,137 |
|
1,065 |
|
Right-of-use assets |
|
|
|
555 |
|
3,448 |
|
740 |
|
Total non-current assets |
|
|
|
1,626 |
|
8,216 |
|
2,195 |
|
|
|
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
|
Inventories |
|
|
|
1,140 |
|
1,573 |
|
1,296 |
|
Trade and other receivables |
|
|
|
2,167 |
|
1,681 |
|
1,744 |
|
Taxation |
|
|
|
- |
|
1,344 |
|
- |
|
Cash and cash equivalents |
|
|
|
2,875 |
|
5,270 |
|
7,349 |
|
Total current assets |
|
|
|
6,182 |
|
9,868 |
|
10,389 |
|
|
|
|
|
|
|
|
|
|
|
Total assets |
|
|
|
7,808 |
|
18,084 |
|
12,584 |
|
Liabilities |
|
|
|
|
|
|
|
|
|
Non-current liabilities |
|
|
|
|
|
|
|
|
|
Lease liabilities |
|
|
|
(884) |
|
(2,811) |
|
(1,000) |
|
Provisions |
|
|
|
(380) |
|
(373) |
|
(618) |
|
Trade and other payables |
|
|
|
- |
|
(56) |
|
- |
|
Total non-current liabilities |
|
|
|
(1,264) |
|
(3,240) |
|
(1,618) |
|
Current liabilities |
|
|
|
|
|
|
|
|
|
Lease liabilities |
|
|
|
(427) |
|
(855) |
|
(817) |
|
Provisions |
|
|
|
(437) |
|
(94) |
|
(434) |
|
Corporation tax payable |
|
|
|
(213) |
|
- |
|
(181) |
|
Trade and other payables |
|
|
|
(1,357) |
|
(2,201) |
|
(2,338) |
|
Total current liabilities |
|
|
|
(2,434) |
|
(3,150) |
|
(3,770) |
|
|
|
|
|
|
|
|
|
|
|
Total liabilities |
|
|
|
(3,698) |
|
(6,390) |
|
(5,388) |
|
Net assets |
|
|
|
4,110 |
|
11,694 |
|
7,196 |
|
Equity |
|
|
|
|
|
|
|
|
|
Share capital |
|
4 |
|
32,673 |
|
32,264 |
|
32,673 |
|
Share premium |
|
|
|
125,299 |
|
118,362 |
|
125,299 |
|
Share-based payments reserve |
|
|
|
411 |
|
3,925 |
|
2,582 |
|
Other reserve |
|
|
|
2,553 |
|
2,553 |
|
2,553 |
|
Translation reserve |
|
|
|
(3,990) |
|
(3,138) |
|
(3,620) |
|
Accumulated losses |
|
|
|
(152,836) |
|
(142,170) |
|
(152,157) |
|
ESOT shares |
|
|
|
- |
|
(102) |
|
(134) |
|
Total equity |
|
|
|
4,110 |
|
11,694 |
|
7,196 |
CELLBXHEALTH PLC
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE SIX MONTHS ENDED
|
|
30 June 2026 (Unaudited) |
|
30 June 2025 (Unaudited) |
|
(Audited) |
|
|
£'000 |
|
£'000 |
|
£'000 |
|
Operating activities |
|
|
|
|
|
|
Loss before tax |
(2,669) |
|
(9,732) |
|
(19,408) |
|
Adjustments for: |
|
|
|
|
|
|
Depreciation and impairment of property, plant and equipment |
293 |
|
413 |
|
1,588 |
|
Depreciation and impairment of right-of-use assets |
267 |
|
409 |
|
1,756 |
|
Loss on disposal of property, plant and equipment |
- |
|
- |
|
56 |
|
Gain on lease termination |
(258) |
|
- |
|
- |
|
Gain on reassessment of lease term on right-of-use assets |
- |
|
- |
|
(54) |
|
Amortisation and impairment of intangible assets |
122 |
|
28 |
|
2,279 |
|
Share-based payment charge/(credit) |
(15) |
|
414 |
|
(752) |
|
Exchange differences |
(354) |
|
2,142 |
|
1,634 |
|
R&D tax credit income |
(169) |
|
- |
|
(956) |
|
Net finance (income)/costs |
18 |
|
55 |
|
159 |
|
Operating cash flows before movements in working capital |
(2,765) |
|
(6,271) |
|
(13,698) |
|
(Increase)/decrease in inventories |
150 |
|
30 |
|
206 |
|
(Increase)/decrease in trade and other receivables |
(256) |
|
346 |
|
1,238 |
|
Increase/(decrease) in trade and other payables |
(882) |
|
(53) |
|
79 |
|
Increase/(decrease) in provisions |
(245) |
|
(86) |
|
515 |
|
Operating cash flows |
(3,998) |
|
(6,034) |
|
(11,660) |
|
Research and development tax credits received |
- |
|
1,436 |
|
2,397 |
|
Net cash from/(used in) operating activities |
(3,998) |
|
(4,598) |
|
(9,263) |
|
Investing activities |
|
|
|
|
|
|
Purchase of property, plant and equipment |
(33) |
|
(87) |
|
(216) |
|
Purchase of intangible assets |
8 |
|
(30) |
|
(33) |
|
Proceeds on disposal of property, plant and equipment |
3 |
|
- |
|
- |
|
Interest received |
50 |
|
96 |
|
126 |
|
Net cash from/(used in) investing activities |
28 |
|
(21) |
|
(123) |
|
Financing activities |
|
|
|
|
|
|
Net proceeds from issue of share capital - placing |
(182) |
|
- |
|
7,623 |
|
Shares acquired by ESOT |
- |
|
- |
|
(32) |
|
Principal elements of lease payments |
(271) |
|
(555) |
|
(1,037) |
|
Interest elements of lease payments |
(55) |
|
(108) |
|
(263) |
|
Net cash from/(used in) financing activities |
(508) |
|
(663) |
|
6,291 |
|
Net increase/(decrease) in cash and cash equivalents |
(4,478) |
|
(5,282) |
|
(3,095) |
|
Cash and cash equivalents at start of period |
7,349 |
|
10,425 |
|
10,425 |
|
Effect of exchange rate fluctuations |
4 |
|
127 |
|
19 |
|
Cash and cash equivalents at end of period |
2,875 |
|
5,270 |
|
7,349 |
CELLBXHEALTH PLC
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE SIX MONTHS ENDED
|
|
------------------------------------------ Equity attributable to owners of the parent -------------------------
|
|||||||
|
|
Share |
Share |
Share-based payments |
Other |
Translation |
Accumulated |
ESOT |
Total |
|
|
capital |
premium |
reserve |
reserve |
reserve |
losses |
shares |
equity |
|
|
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
|
At |
32,264 |
118,362 |
3,754 |
2,553 |
(5,245) |
(133,145) |
(102) |
18,441 |
|
For the period to |
|
|
|
|
|
|
|
|
|
Consolidated loss |
|
|
|
|
|
(9,268) |
|
(9,268) |
|
Other comprehensive income/(loss) |
|
|
|
|
2,107 |
|
|
2,107 |
|
Total comprehensive income/(loss) |
|
|
|
|
2,107 |
(9,268) |
|
(7,161) |
|
Share-based payment expense |
|
|
414 |
|
|
|
|
414 |
|
Released on forfeiture/lapse |
|
|
(243) |
|
|
243 |
|
- |
|
Total transactions with owners
|
|
|
171
|
-
|
-
|
243
|
-
|
414
|
|
At |
32,264 |
118,362 |
3,925 |
2,553 |
(3,138) |
(142,170) |
(102) |
11,694 |
|
|
|
|
|
|
|
|
|
|
|
For the period to |
|
|
|
|
|
|
|
|
|
Consolidated loss |
|
|
|
|
|
(10,241) |
|
(10,241) |
|
Other comprehensive income/(loss) |
|
|
|
|
(482) |
|
|
(482) |
|
Total comprehensive income/(loss) |
|
|
|
|
(482) |
(10,241) |
|
(10,723) |
|
Issue of shares (net of costs) |
409 |
7,014 |
|
|
|
|
|
7,423 |
|
Shares acquired by ESOT |
|
|
|
|
|
|
(32) |
(32) |
|
Share-based payment credit |
|
|
(1,166) |
|
|
|
|
(1,166) |
|
Equity-settled share-based payment - broker warrants |
|
(77) |
77 |
|
|
|
|
- |
|
Released on forfeiture/lapse |
|
|
(254) |
|
|
254 |
|
- |
|
Total transactions with owners
|
409
|
6,937
|
(1,343)
|
-
|
-
|
254
|
(32)
|
6,225
|
|
At |
32,673 |
125,299 |
2,582 |
2,553 |
(3,620) |
(152,157) |
(134) |
7,196 |
|
|
|
|
|
|
|
|
|
|
|
For the period to |
|
|
|
|
|
|
|
|
|
Consolidated loss |
|
|
|
|
|
(2,701) |
|
(2,701) |
|
Other comprehensive income/(loss) |
|
|
|
|
(370) |
|
|
(370) |
|
Total comprehensive income/(loss) |
|
|
|
|
(370) |
(2,701) |
|
(3,071) |
|
Settlement of employee share awards using ESOT shares |
|
|
(134) |
|
|
|
134 |
- |
|
Share-based payment credit |
|
|
(15) |
|
|
|
|
(15) |
|
Released on exercise |
|
|
(1,529) |
|
|
1,529 |
|
- |
|
Released on forfeiture/lapse |
|
|
(493) |
|
|
493 |
|
- |
|
Total transactions with owners
|
-
|
-
|
(2,171)
|
-
|
-
|
2,022
|
134
|
(15)
|
|
At |
32,673 |
125,299 |
411 |
2,553 |
(3,990) |
(152,836) |
- |
4,110 |
CELLBXHEALTH PLC
NOTES TO THE CONDENSED INTERIM FINANCIAL INFORMATION
FOR THE PERIOD ENDED
1. Preliminary announcement
The Condensed Interim Financial Information is the unaudited interim consolidated financial information (the "Condensed Interim Financial Information") of CelLBxHealth plc, a company incorporated and domiciled in
The Condensed Interim Financial Information should be read in conjunction with the Financial Statements of the Group for the year ended
The accounting policies used in the preparation of the Condensed Interim Financial Information for the six months ended
The Condensed Interim Financial Information does not constitute statutory financial statements as defined in section 434 of the Companies Act 2006 and is unaudited and has not been reviewed. The comparative information for the six months ended
The Condensed Interim Financial Information was approved by the Board and authorised for issue on
Going concern
The Financial Statements have been prepared on a going concern basis. In adopting this basis, the Directors have assessed the Group's ability to continue as a going concern for a period of at least 12 months from the date of approval of these Financial Statements, taking into account all available information.
The Group's business activities, together with the factors likely to affect its future development, performance and financial position, are set out in the Executive Chairman's letter and the Chief Executive's Statement.
At
The Directors have prepared a detailed monthly forecast to
The Directors believe several potential funding sources are available to the Group, including revenues, commercial milestones, licensing income, and debt or equity financing. However, based on current forecasts, the Group will require additional funding to continue operations beyond Q2 2027. There can be no certainty that such funding will be obtained on acceptable terms, or at all.
The Group's forecasts are dependent upon the successful and timely conversion of a number of significant commercial opportunities into revenue, the timing and extent of which remain uncertain. A significant proportion of forecast revenues is concentrated within a relatively small number of opportunities and customers, and many pipeline opportunities remain at proposal stage. There can be no certainty that forecast revenues will be achieved in line with management's expectations. These conditions, together with the requirement for additional funding beyond Q2 2027, represent a material uncertainty that may cast significant doubt on the Group's ability to continue as a going concern. Notwithstanding this, the Directors have a reasonable expectation that the Group will be able to secure the necessary funding and meet its liabilities as they fall due. As a result, the Financial Statements continue to be prepared on a going concern basis and do not include any adjustments that would result if the Group were unable to continue as a going concern.
Critical accounting estimates and judgements
The preparation of the Financial Statements requires management to make judgements and estimates that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. There were no areas of significant judgement or key sources of estimation uncertainty in preparing these Financial Statements.
2. Tax
The Group undertakes research and development activities. During the period the Group recognised income under the
3. Loss per share attributable to owners of the parent
Basic and diluted loss per share is calculated by dividing the loss attributable to owners of the parent of
As the Group reported a loss in the current and comparative periods, potentially dilutive share options have not been included in the calculation of diluted loss per share as they are anti-dilutive. As a result, diluted loss per share is equal to basic loss per share.
The weighted average number of ordinary shares used in the calculation was 1,136,767,299 (six months to
4. Share capital
The Company has one class of ordinary shares which carry no right to fixed income. The deferred shares carry no voting rights and have restricted rights to dividends and on a return of capital as set out in the Company's Articles of Association.
At
5. Shareholder communications
This announcement is being sent to all shareholders on the register at
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE